The Lynx Group

Jeffrey Weber, MD, PhD


Authored Items

Nivolumab: Impressive Responses in Melanoma

October 2014, Vol 3, No 7 - Uncategorized

Immunotherapy marches on showing continued progress in treating advanced melanoma. At the recent ESMO 2014 Congress, first reports from a phase 3 study showed that the monoclonal anti–PD-1 antibody nivolumab achieved superior responses and longer duration of response compared with standard chemotherapy in the second- or third-line treatment of patients [ Read More ]

Sign me up!